Public disclosures

JEAN CHRISTOPHE

Company insiders · Director · RHYTHM PHARMACEUTICALS, INC.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-18.Following & alerts
Reported transaction lines
5
Buy lines
0
Sell lines
3

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-115

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
JEAN CHRISTOPHE

Director · RHYTHM PHARMACEUTICALS, INC.

RYTM

RHYTHM PHARMACEUTICALS, INC.

Exercise or conversion
Filing details

SEC transaction code M

Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 0 · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026. · The options fully vested upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders.

2026-11-172026-11-18

10,000 shares/units

SEC 4
JEAN CHRISTOPHE

Director · RHYTHM PHARMACEUTICALS, INC.

RYTM

RHYTHM PHARMACEUTICALS, INC.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 11712 · SEC code covers open-market or private transactions · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026.

2026-11-172026-11-18

≈ $287,500.00

2,500 shares/units

SEC 4
JEAN CHRISTOPHE

Director · RHYTHM PHARMACEUTICALS, INC.

RYTM

RHYTHM PHARMACEUTICALS, INC.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 14212 · SEC code covers open-market or private transactions · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026.

2026-11-172026-11-18

≈ $275,000.00

2,500 shares/units

SEC 4
JEAN CHRISTOPHE

Director · RHYTHM PHARMACEUTICALS, INC.

RYTM

RHYTHM PHARMACEUTICALS, INC.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 16712 · SEC code covers open-market or private transactions · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026.

2026-11-172026-11-18

≈ $534,050.00

5,000 shares/units

SEC 4
JEAN CHRISTOPHE

Director · RHYTHM PHARMACEUTICALS, INC.

RYTM

RHYTHM PHARMACEUTICALS, INC.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 21712 · The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2026.

2026-11-172026-11-18

10,000 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement